Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Are β-blockers associated with lower rates of mortality and morbidity after cardiac or noncardiac surgery?
In cardiac surgery, β-blockers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arrhythmias. In noncardiac surgery, β-blockers are associated with a possible increase in mortality and strokes, a lower incidence of acute myocardial infarctions (AMIs) and SVTs, and an increase in bradycardia and hypotension. If tolerated, long-term β-blocker treatment should be continued perioperatively, whereas the decision to start a β-blocker should be individualized, weighing risks and benefits.
Blessberger H, Kammler J, Steinwender C. Perioperative Use of β-Blockers in Cardiac and Noncardiac Surgery. JAMA. 2015;313(20):2070–2071. doi:10.1001/jama.2015.1883
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: